Skip to main content

Werewolf Therapeutics, Inc.

HOWL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001785530

In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Werewolf Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of HOWL: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders4251+9
Shares19.0M19.1M+132.8K (+0.7%)
Value$326.2M$228.3M−$98.0M (−30.0%)

New holders (12)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to HOWL in Q4 2021
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP22,034$262.0K0.00%
Rhumbline Advisers19,305$230.0K0.00%
Granite Point Capital Management, L.P.15,000$179.0K0.07%
Manufacturers Life Insurance Company, The12,831$153.0K0.00%
Wells Fargo & Company12,699$151.0K0.00%
Susquehanna International Group, LLP11,829$141.0K0.00%
MetLife Investment Management11,421$136.0K0.00%
Goldman Sachs Group Inc10,080$120.0K0.00%
Metropolitan Life Insurance Co8,460$100.8K0.00%
High Net Worth Advisory Group LLC500$6.00K0.00%
Daiwa Securities Group Inc.80$1.00K0.00%
Confluence Wealth Services, Inc.100$1.00K0.00%

Sold out (3)

Institutions that held Werewolf Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of HOWL in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Nicholas Investment Partners, LP296,283$5.08M
Russell Investments Group, Ltd.125,873$2.16M
Levin Capital Strategies, L.P.15,000$257.0K